Skip to main
TMCI

TMCI Stock Forecast & Price Target

TMCI Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 75%
Sell 25%
Strong Sell 0%

Bulls say

Treace Medical Concepts Inc. is experiencing growth in active surgeon users, which increased by 7.0% year-over-year to approximately 3,285, although utilization per surgeon has slightly declined. The company's strategic initiatives, including enhanced direct-to-consumer programs, improved physician education, and a bolstered sales force, are expected to contribute to modest revenue growth and potential margin improvements as average selling prices (ASPs) rise. Furthermore, the expansion of TMCI's product offerings beyond the Lapiplasty system aims to capture a larger market share in complementary foot and ankle procedures, positioning the company for long-term growth and a positive revenue outlook.

Bears say

Treace Medical Concepts Inc. is facing a negative financial outlook characterized by a projected revenue decline of approximately 10% year-over-year for the fourth quarter, with expected revenues of $61.8 million falling short of historical performance. The company's guidance for fiscal year 2025 has also been lowered to a range of $211-213 million, attributed to decreased volumes in elective bunion procedures and ongoing headwinds related to their Lapiplasty procedure. Additionally, with forecasts indicating negative year-over-year growth for 2026 before a modest recovery in 2027, the company's valuation multiple is expected to remain flat or decline further, reflecting a challenging market environment.

TMCI has been analyzed by 4 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 75% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Treace Medical Concepts and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Treace Medical Concepts (TMCI) Forecast

Analysts have given TMCI a Hold based on their latest research and market trends.

According to 4 analysts, TMCI has a Hold consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Treace Medical Concepts (TMCI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.